P3.16-19 Clinical Outcomes of Stereotactic Body Radiation Therapy for T2N0M0 Non-Small Cell Lung Cancer

Abstract

For patients with inoperable stage I non-small cell lung cancer (NSCLC), stereotactic body radiation therapy (SBRT) is considered standard. However, the effectiveness and safety of SBRT specifically for T2N0M0 NSCLC remains controversial. This retrospective study investigated the safety and efficacy of SBRT in T2N0M0 NSCLC. The medical records of 29 patients with T2N0M0 NSCLC treated by SBRT were reviewed. The overall, progression-free, and cause-specific survival rates were determined. The mean follow-up was 20.1 months. At years 1, 2, and 3, the overall survival rates were 93.1, 93.1, and 89.7%, respectively; the corresponding cause-specific survivals were 96.6, 96.6, and 93.1%; the progression-free survivals were 75.9, 65.5, and 62.1%; the local control rates were 100, 96.6, and 96.6%; the regional control was 86.2, 79.3, and 75.9%; and distant control was 89.7, 82.8, and 79.3%. Twenty patients (69.0%) developed symptoms of grade 1 toxicity: dyspnea, chest pain, fatigue, cough, esophagitis, or pneumonia. Among these, 5 patients suffered grade ≥2 therapy-associated pneumonitis, and one patient experienced grade 4 adverse pulmonary effects. SBRT was efficient and safe for patients with inoperable T2N0M0 NSCLC, imposing tolerable toxicities. These results warrant a prospective study to develop the multidisciplinary criteria for SBRT in T2N0M0 NSCLC.